Loading
Life sciences · Journal article
Theoretical and Natural Science · September 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Circulating tumour DNA (ctDNA) in blood is now used in a less invasive way to guide personalised cancer therapy. Several blood tests can be conducted on ctDNA to determine whether there is a distant spread of cancer cells, discover microscopic cancer cells remaining after surgery, and observe how the immune system responds to immunotherapy in time; thus, repeated tissue biopsies and delayed CT scans are reduced. The previous way of diagnosis cannot rapidly identify gene mutations in lesions, and frequent ctDNA tests can promptly detect cross-regional and time-dependent genomic alterations to provide real-time molecular support for clinical decisions. This paper first sorts out updated performance and lingering defects of current ctDNA detection platforms, then analyzes real clinical data covering four major tumor types: breast malignancies, colorectal carcinoma, melanoma, non-small cell lung cancer (NSCLC). Multiple prospective cohort observations and pooled meta-analysis data show that ctDNA surveillance can divide patients into high- and low-risk groups for recurrence, detect molecular relapse months before any visible lesion enlargement on scans, and identify newly arising drug-resistant mutant clones ahead of imaging signals. All collected clinical evidence shows that ctDNA serves as a daily diagnostic aid to continuously optimise the entire implementation logic of personalised tumour immunotherapy.